Bulletin
Investor Alert

Market Pulse Archives

May 15, 2020, 6:14 a.m. EDT

ADC Therapeutics prices IPO at $19 a share, above the price range

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    ADC Therapeutics S.A. (ADCT)
  • X
    Renaissance IPO ETF (IPO)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

ADC Therapeutics S.A. /zigman2/quotes/214411413/composite ADCT -0.13% priced its initial public offering at $19 a share late Thursday, above its proposed price range of $16 to $18, and increased the size to 12.2 million shares from 10.3 million when it set terms. The Swiss biotechnology company focused on cancer treatments raised $233 million with proceeds to be used to fund clinical research. The stock will start trading on the NYSE later Friday under the ticker symbol "ADCT." Morgan Stanley, BofA Securities and Cowen were the lead underwriters on the deal. The company recorded a net loss of $116.5 million on contract revenue of $2.3 million in 2019, compared with a loss of $123.1 million on revenue of $1.1 million in 2018. ADC is going public at a time that the Renaissance IPO ETF /zigman2/quotes/207665280/composite IPO -4.67% has slipped 4% over the past three months while the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.89% has dropped 16%.

/zigman2/quotes/214411413/composite
US : U.S.: NYSE
$ 15.67
-0.02 -0.13%
Volume: 214,431
Jan. 21, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.20 billion
Rev. per Employee
$81,284
loading...
/zigman2/quotes/207665280/composite
US : U.S.: NYSE Arca
$ 44.67
-2.19 -4.67%
Volume: 326,133
Jan. 21, 2022 4:10p
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,397.94
-84.79 -1.89%
Volume: 3.20B
Jan. 21, 2022 4:52p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.